Lassa epidemiological studies
Expression of interest: epidemiological studies of Lassa fever in West Africa
CEPI plans to provide grants for epidemiological studies of Lassa virus that will inform future trial design, endpoints, and site selection for Lassa-vaccine development.
As part of this “expression of interest” process, CEPI would like to identify research groups that are interested in performing such studies. Such groups can be composed of investigators based anywhere in the world, but the Principal Investigator must be from a Lassa-endemic country, and the consortium must include local co-investigators at each proposed study site.
The expression of interest will serve as a prequalification to apply for funding through a subsequent “request for proposals” on epidemiological studies of Lassa virus.
Points to consider
- Groups are eligible if they have strong local presence in a Lassa-endemic region(s) and previous experience with Lassa field studies.
- All work conducted under this expression of interest and subsequent calls is expected to involve local investigators, and to contribute to strengthening of local clinical-research capacity.
- Applicants selected through this expression of interest will receive “prequalification” to apply for funding through a formal request for proposals (RfP) to be launched at the end of 2018.
- “Prequalified” applicants will be expected to participate in a workshop in Q4 2018 to provide input on harmonising the core study protocol that CEPI will use for the RfP.
Deadline for submission is 12.00 CEST on 30 August 2018. Applicants will be informed of selection results by October 2018.
Equitable Access policy
Request for public comments: CEPI’s Equitable Access policy
CEPI is committed to achieving equitable access to the vaccines it helps to develop. Following our launch at Davos in January 2017 we developed a policy regarding CEPI’s approach to equitable access that was approved for a one-year trial period, with the intent to review and if necessary revise it based on lessons learned.
We are now well into that review, which involved consultation with a wide range of our stakeholders, and have made a number of revisions in how we present our policy. Since the consultation process could not, as a matter of practicality, involve all those who wish to contribute, we are also seeking wider consultation and feedback before we finalise our equitable access policy.
Request for proposals: biological standards to support and accelerate Lassa fever vaccine development
Biological standards play a critical role in advancing vaccine development. International standards enable the harmonization and standardization of assay data, which in turn allows the evaluation and on-going quality control of a product throughout its life cycle. Proper standards and common assays allow comparison between different vaccines and enable different groups to provide comparable data about a given vaccine.
In this invitation, CEPI asks for the submission of proposals for one or more of the following:
- Studies to obtain sera from Lassa-fever survivors, suitable for the development of serum standard and panels against Lassa fever
- Provision of recombinant antigens [Lassa virus (LASV) glycoprotein (GP) and nucleoprotein (NP)]
- Development of interim standard(s) through characterization, evaluation, and processing of antigens and serum
- Storage and provision of antigen(s) and serum to ensure long-term access by Lassa-vaccine developers
Timeline and key dates:
- Submission deadline for proposals is August 6th, 2018, at 12:00 CEST
- Due diligence and contract negotiations initiated in September 2018
- Contract signing in Q4 2018
Responses to CEPI's second call for proposals
On 1st September, CEPI launched its Second Call for Proposals (CfP) on Vaccine platform technologies to promote the objective of developing development of real time response capabilities to novel emerging threats, and immunize at-risk populations against emerging infectious diseases, potentially resulting in great public health impact by rapidly limiting or ending outbreaks.
In response to this Call for Proposals, the Secretariat received over 35 applications by the deadline of 17 October, with a broad diversity displayed in the vaccine platform technologies being proposed, including both novel concepts and established technologies. All eligible submissions are now being evaluated, and shortlisted applicants will be notified in December to submit detailed proposals in early 2018.
Similar to our previous call, applicants and their partners are from North America, South America, Europe, Africa, Asia and Australia, representing academic institutions, biotechs, large pharmaceutical companies and Product Development Partnerships.More information
Work on Ebola
The "Ebola vaccines regulatory scientific meeting" enabled us to look into future regulatory scientific research areas which will be further refined and taken forward in smaller task forces. Updates on how we will proceed the work on Ebola will be published on our website and Newsletter.
The summary report can be found here.